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SYSTEMATIC REVIEW

Major Publications in the Critical Care
Pharmacotherapy Literature: 2020
OBJECTIVES: To summarize selected meta-analyses and trials related to critical
care pharmacotherapy published in 2020.

Brittany D. Bissell, PharmD, PhD,
BCCCP1
Jeannee Campbell, PA2
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DATA SOURCES: The Clinical Pharmacy and Pharmacology Pharmacotherapy
Literature Update group screened 36 journals monthly for impactful publications.

Reagan Collins, PharmD, BCCCP3

STUDY SELECTION: The group reviewed a total of 119 articles during 2020
according to relevance for practice.

Dharati Desai, PharmD, BCCCP5

DATA EXTRACTION: Articles were selected with consensus and importance
to clinical practice from those included in the monthly Clinical Pharmacy and
Pharmacology Pharmacotherapy Literature Update. The group reviewed articles
according to Grading of Recommendations, Assessment, Development, and
Evaluations criteria. Articles with a 1A grade were selected.

Ifeoma Mary Eche, PharmD,
BCPS, BCCCP, CACP4

DATA SYNTHESIS: Several trials were summarized, including two meta-analyses and five original research trials. Original research trials evaluating vitamin
C, hydrocortisone, and thiamine versus hydrocortisone in sepsis, the use of nonsedation strategies, dexmedetomidine in cardiac surgery, remdesivir for severe
acute respiratory syndrome coronavirus 2, and thrombectomy in acute ischemic
stroke. Two meta-analyses determining the impact of norepinephrine initiation in
patients with septic shock and the use of corticosteroids in severe acute respiratory syndrome coronavirus 2 was included.
CONCLUSIONS: This clinical review provides summary and perspectives of clinical
practice impact on influential critical care pharmacotherapy publications in 2020.
KEY WORDS: coronavirus disease 2019; critical care; drug therapy; review;
sedation; septic shock

C

ritical care practitioners commit significant time staying up-to-date
with the most pertinent medical literature (1). As such, clinicians rely
on electronic table of contents, social media, blogs, and article synopses to provide a summary of relevant literature (2). In 2009, a group of critical
care pharmacists developed a process for updating practitioners on new critical care pharmacotherapy literature resulting in the Clinical Pharmacy and
Pharmacology Pharmacotherapy Literature Update (CPPPLU), a monthly publication summarizing new literature. Currently, under the Clinical Pharmacy
and Pharmacology (CPP) Section of the Society of Critical Care Medicine
(SCCM), monthly reviews continue with annual review of the most impactful
literature for the year (3–6).

MATERIALS AND METHODS
Monthly, the CPPPLU workgroup evaluates and selects articles relevant to
critical care practice systematically from 36 journals based on importance
and relevance to practice (Appendix A). For inclusion, articles must meet the
following criteria: 1) controlled trial, observational, meta-analysis or major
Critical Care Explorations
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guideline/guideline update; 2) adult patient population; 3) addresses critical care and involving drug
therapy (including fluid and nutritional therapy, drugimpregnated lines, and dialysis in the ICU or percutaneous coronary interventions); and 4) published in
current monthly issue. Articles that do not meet such
criteria and those that are published online ahead-ofprint are excluded. CPPPLU members are assigned
journals for monthly evaluation and abstraction and
assign a Grading of Recommendations, Assessment,
Development, and Evaluations (GRADE) score upon
extraction (7). Currently, the CPPPLU is distributed
globally to the membership of SCCM through a webbased platform and social media. From 119 articles
reviewed in 2020, articles that were GRADE 1A were
evaluated for annual review. Articles that appeared to
have high impact were selected in addition to consideration for breadth of critical care medication category and specialty pertinence. All authors agreed with
selected content and the article as well as its content
were approved by the SCCM CPP Steering Committee
and SCCM Council.

RESULTS
Over the course of the year, 26 articles were analyzed
for inclusion into this article. Two meta-analyses and
five clinical research trials were selected for review for
this annual publication on the basis of GRADE criteria
(1A), pharmacotherapeutic focus, and expected practice influence (8–13). Table 1 provides a summary of
the studies selected for discussion.

DISCUSSION
Coronavirus Disease 2019
Remdesivir in Adults With Severe Coronavirus
Disease 2019: A Randomized, Double-Blind, PlaceboControlled, Multicenter Trial. This randomized, placebo-controlled, double-blind trial evaluated remdesivir
200 mg on day one followed by 100 mg daily on days 2–10
in hospitalized adults with severe, laboratory-confirmed
coronavirus disease 2019 (COVID-19) pneumonia (11).
Those exhibiting oxygen saturation of less than or equal
to 94% on room air or an Pao2 to Fio2 ratio of less than
or equal to 300 mm Hg within 12 days of symptom
onset were included. Median time from symptom onset
to treatment randomization was 10 days. The majority
2     www.ccejournal.org

of patients were categorized at baseline as a “three” on
6-point clinical status ordinal scale (six = death, three =
hospitalized with supplemental oxygen, one = discharge
eligible). The trial was terminated early due to control of
the outbreak in Wuhan, reducing statistical power from
80% to 58% (n–237).
In the intention to treat analysis, remdesivir showed
no difference in time to clinical improvement (21 d vs 23
d; hazard ratio, 1.23; 95% CI, 0.87–1.75) or 28-day mortality (14% vs 13%; difference, 1.1%; CI, –8.1 to 10.3).
Those receiving remdesivir within 10 days of symptom
onset exhibited a numerically faster time to clinical
improvement and numerically higher clinical improvement rates at days 14 and 28. Ultimately, remdesivir conferred no statistical difference in either
clinical improvement or mortality compared with placebo, although severely underpowered due to early
termination.
Numerous trials have evaluated remdesivir for COVID-19 displaying similar results. The
Adaptive COVID-19 Treatment Trial-1 study demonstrated significantly reduced time to recovery
(10 vs 15 d; recovery rate ratio [RR], 1.29; 95% CI,
1.12–1.49; p < 0.001) and higher clinical improvement scores at day 15 (odds ratio [OR], 1.5; 95%
CI, 1.2–1.9; p < 0.001) with remdesivir (15). Specifically,
the subgroup of patients requiring supplemental oxygen (not via means of high-flow nasal cannula or
noninvasive ventilation) and those receiving treatment
less than 10 days from symptom onset gleaning the
most benefit. The World Health Organization (WHO)
Solidarity trial compliments this, finding no mortality
benefit (RR, 0.95; 95% CI, 0.81–1.11; p = 0.50), but numerically lower deaths in lower risk patients not requiring ventilation (RR, 0.80; 95% CI, 0.63–1.01) (16).
Aforementioned trials included 10-day remdesivir
courses; however, studies evaluating 5- and 10-day
courses revealed no difference in clinical status or improvement between the two durations (17, 18).
Wang et al (11), combined with available literature,
may suggest a role for 5 days of remdesivir in low-risk,
hospitalized patients receiving noninvasive oxygenation
within 10 days of symptom onset to prevent risk of deterioration. Remdesivir may curtail duration of illness,
expediting time to hospital discharge, which could greatly
impact limited healthcare resources. Current guidelines
recommend against its use in patients on invasive ventilation or extracorporeal membrane oxygenation (19).
December 2021 • Volume 3 • Number 12
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TABLE 1.

Article Summary
References

Population

Intervention

Design

Outcomes

Fujii et al (8)

Two-hundred eleven patients Vitamin C,
Multicenter,
with septic shock,
hydrocortisone,
open-label,
vasopressor dependent
thiamine vs
parallel-group,
for at least 2 hr
placebo
randomized
controlled

No difference in time alive and free of
vasopressors at day 7

Li et al (13)

Nine-hundred twenty-nine
Early vs later
adult patients with septic
norepinephrine
shock
initiation

Meta-analysis

Short-term mortality was lower with
early norepinephrine group

Olsen
et al (9)

Seven-hundred ten
mechanically ventilated
patients

Multicenter,
randomized,
nonblinded
study

No difference in all-cause 90-d
mortality, delirium-free days,
mechanical ventilation duration

Turan
et al (10)

Seven-hundred ninety-eight
Dexmedetomidine Multicenter,
adult patients undergoing
vs placebo
randomized
cardiac surgery with
cardiopulmonary bypass and
heart rate > 50 beats/min

Light sedation vs
nonsedation

High heterogeneity

Rapid Evidence One-thousand sevenCorticosteroids vs Meta-analysis of
Appraisal for
hundred three critically ill
placebo
randomized
COVID-19
patients with COVID-19
trials
Therapies
(REACT)
Working
Group et al
(14)
Wang
et al (11)

Two-hundred thirty-seven
adults with severe,
laboratory-confirmed
COVID-19 pneumonia

Yang
et al (12)

Six-hundred fifty-six
Thrombectomy
adults with large vessel
alone vs in
occlusion and National
combination
Institute of Health Stroke
with alteplase
Scale of at least two

Remdesivir vs
placebo

No difference in postoperative atrial
fibrillation
Increase in clinically significant
hypotension with dexmedetomidine
Decreased 28-d mortality with
steroids
Minimal heterogeneity reported, but
several corticosteroid regimens
used

Randomized,
No difference in time to clinical
double-blind trial
improvement or mortality

Prospective,
randomized,
open-label trial

Modified Rankin score at 90 d
with thrombectomy alone vs
combination was noninferior
No difference in mortality, severe
adverse events, or procedural
complications

COVID-19 = coronavirus disease 2019.

WHO Rapid Evidence Appraisal for COVID-19
Therapies (REACT) Working Group et al. Administration
of Systemic Corticosteroids and Mortality Among Critically
Ill Patients With COVID-19: A Meta-Analysis. The use of
corticosteroids for the treatment of viral pneumonias has
been a widely debated controversy (14). Prior to the publication of studies evaluating its effect in severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), practice guidelines
from multiple organizations cautioned against the routine use of corticosteroids in patients with COVID-19
Critical Care Explorations

pneumonia (20). This recommendation was largely
based on experiences with other viruses such as influenza, SARS-CoV, and Middle East respiratory syndrome coronavirus, in which corticosteroids have
been associated with delayed viral clearance and worse
clinical outcomes (21, 22). However, corticosteroids
became standard practice for the treatment of COVID19 pneumonia after the publication of the Randomized
Evaluation of COVID-19 Therapy (RECOVERY) trial
that suggested a mortality benefit (23).
www.ccejournal.org
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The WHO Rapid Evidence Appraisal for COVID-19
Therapies (REACT) Working Group conducted a prospective meta-analysis of randomized trials to estimate
the association between corticosteroids versus usual
care or placebo and 28-day all-cause mortality in hospitalized, critically ill patients with COVID-19 (14).
Trials were identified by trial registries until April 2020
and data were pooled from patients recruited to trials
by June 9, 2020. Patients recruited after the release of
the results of the RECOVERY trial were not included
in the analysis. Of 16 trials identified, seven were included in the final meta-analysis with 1,703 critically ill
patients (678 to corticosteroids and 1,025 to usual care/
placebo). Corticosteroid therapies included low and
high-dose dexamethasone (three studies), low-dose
hydrocortisone (three studies), and high-dose methylprednisolone (one study). A majority of patients were
on mechanical ventilation (91.5%), and 47% were on
vasoactive agents at randomization. Five trials reported
mortality at 28 days, one at 21 days, and one at 30 days.
The primary outcome, all-cause mortality at 28
days, was lower in the steroid arm compared with
the no steroid arm based on a fixed-effect meta-analysis (32.7% vs 41.5%; OR, 0.66; 95% CI, 0.53–0.82;
p < 0.001). Dexamethasone was associated with lower
all-cause mortality (OR, 0.64; 95% CI, 0.50–0.82;
p < 0.001), while hydrocortisone (OR, 0.69; 95% CI, 0.43–
1.12; p = 0.13) and methylprednisolone (OR, 0.91; 95%
CI, 0.29–2.87; p = 0.87) were not. In subgroup analyses, among patients receiving invasive mechanical
ventilation, the OR for mortality associated with corticosteroids compared with usual care was 0.69 (95% CI,
0.55–0.86) and among those that were not on invasive
ventilation, the OR was 0.41 (95% CI, 0.19–0.88). There
was also a stronger association between corticosteroids
and lower mortality in patients who were not receiving
vasoactive medications (OR, 0.55; 95% CI, 0.34–0.88)
than those who were (OR, 1.05; 95% CI, 0.65–1.69).
The authors concluded that corticosteroid administration was associated with a lower all-cause mortality
without evidence suggesting an increased risk of serious adverse events (14). The analysis reports minimal
heterogeneity with I2 of 15.6% (p = 0.31); however, the
included trials had substantial differences in the definition of illness, steroid choice and dose, duration of
therapy, and reporting of adverse events. Particularly,
the three steroids used have different durations of activity, dosing strategies, and potency of mineralocorticoid or glucocorticoid activities. The RECOVERY
4     www.ccejournal.org

trial, which used low-dose dexamethasone, contributed 57% of the weight in the primary outcome of allcause mortality. In contrast, only one study evaluated
the effect of methylprednisolone and contributed 3.5%
of the weight in the primary analysis. Given the high
percentage of patients receiving dexamethasone in this
analysis, the mortality benefit of alternative steroids,
such as methylprednisolone remains to be determined.
Uncertainties remain in regards to appropriate dosing
and duration of corticosteroids in different severities
of critical illness or ventilatory support, as well as the
additive effect of adjunctive therapies for COVID-19
such as remdesivir.
Sepsis and Septic Shock
Effect of Vitamin C, Hydrocortisone, and Thiamine
Versus Hydrocortisone Alone on Time Alive and Free
of Vasopressor Support Among Patients With Septic
Shock (VITAMINS). The VITAMINS trial was a multicenter, open-label, parallel-group, randomized controlled
trial (RCT) evaluating resolution of shock with vitamin
C (1.5 g every 6 hr), hydrocortisone (50 mg every 6 hr),
and thiamine (200 mg every 12 hr) (HAT) therapy (8).
Patients in septic shock who were vasopressor dependent for at least 2 hours were randomized to HAT
therapy (n = 107) versus the control group of hydrocortisone alone (n = 104) with treatment durations until
shock resolution or up to 10 days.
Baseline characteristics were similar between
groups, except the HAT therapy group had numerically
higher lactate levels (median, 4.2 vs 3.3 mmol/L). Mean
baseline Sequential Organ Failure Assessment (SOFA)
scores were similar in the HAT and control groups (8.6
vs 8.4, respectively). There was no difference in the primary outcome of time alive and free of vasopressors
at day 7 (median 122.1 vs 124.6 hr in HAT therapy vs
control group, respectively; p = 0.83) or 28- and 90-day
mortality. The change in SOFA score was significantly
greater with HAT therapy at day 3 compared with the
control group (median –2 vs –1; p = 0.02). The mean
duration of either therapy was 3.4 days.
In 2017, Marik et al (24) observed a significant reduction in duration of vasopressor use and hospital
mortality in patients with severe sepsis or septic shock
who received HAT therapy versus standard of care.
This set forth several trials evaluating the impact of
HAT combination on morbidity and mortality outcomes, each with slightly different study designs. The
December 2021 • Volume 3 • Number 12
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VITAMINS study, which only enrolled septic shock
patients with the control arm receiving hydrocortisone, disputed the Marik et al (24) findings, as there
was no difference in the primary outcome or secondary outcomes of 28- and 90-day mortality (8).
The improvement in SOFA score at day 3 in the HAT
therapy group was not corroborated in two additional
studies at 4 days and 72 hours, respectively (8, 25, 26).
Both the Outcomes of Metabolic Resuscitation Using
Ascorbic Acid, Thiamine, Glucocorticoids in the Early
Treatment of Sepsis (ORANGES) and Ascorbic Acid,
Corticosteroids, and Thiamine in Sepsis (ACTS) trials
found faster time to resolution of shock in the HAT
therapy group versus placebo, unlike the VITAMINS
trial (25, 26). However, there is well-established evidence that the use of hydrocortisone reduces time to
resolution of shock and only 41% and 14% of patients
in the placebo arms of the ORANGES and ACTS trials
received corticosteroids, respectively (27, 28). Current
available evidence does not support the routine use of
HAT therapy over hydrocortisone alone for resolution
of shock or for improvement of mortality in patients
with sepsis.
Timing of Norepinephrine Initiation in Patients With
Septic Shock: A Systematic Review and Meta-Analysis.
In the systematic review and meta-analysis conducted
by Li et al (13), early norepinephrine use was compared
with late initiation of norepinephrine in patients with
septic shock. A random-effects model was used to pool
studies with significant heterogeneity. Five studies with
a combined sample size of 929 adult patients were included (29–32). The five studies were analyzed for the
primary endpoint of short-term mortality. Short-term
mortality was defined as hospital, 28-day, and 30-day
mortality. Three (60%) of the included studies were analyzed for these secondary outcomes: ICU length of stay,
time to achieve target mean arterial pressure (MAP),
and volume of IV fluids (IVFs) within 6 hours (29–32).
While there was no significant heterogeneity found
among the studies for short-term mortality (I2 = 0%),
ICU length of stay (I2 = 0%), and time to target MAP
(I2 = 0%), there was substantial heterogeneity present for
volume of IVF within 6 hours (I2 = 94%). Short-term
mortality was lower in the early norepinephrine group
compared with the late norepinephrine group (OR, 0.45;
95% CI, 0.34–0.61). There was no significant difference
in ICU length of stay (mean difference = –0.11 d; 95%
CI, –1.27 to 1.05). However, the early norepinephrine
Critical Care Explorations

group had shorter time to target MAP (mean difference = –1.39 hr; 95% CI, –1.81 to –0.96 hr) and used
less IVF within 6 hours (mean difference = –0.50 L; 95%
CI, –0.68 to –0.32 L).
Norepinephrine remains the first-line vasopressor
for septic shock (33). Although the surviving sepsis
guidelines recommend use of vasopressors early in the
course of septic shock, the impact on clinical outcomes
remains unclear (34). The 2018 update to the Surviving
Sepsis Guidelines recommends rapid administration
of crystalloid within the first hour of septic shock
and early application of vasopressors in patients who
remain hypotensive despite fluid resuscitation (34).
Consistent with the guidelines, the findings of this
meta-analysis support the use of norepinephrine early
in the course of septic shock. Early administration of
norepinephrine shortens the duration of hypotension
and provides adequate perfusion to prevent organ
damage (34). Additionally, the use of vasopressors
early may minimize the use of unnecessary fluids beyond the initial resuscitation period.
Although the aforementioned guideline recommendations for early vasopressor initiation are part of the
1-hour sepsis bundle, the most optimal timing is still
unclear. The studies included in this meta-analysis had
variable definitions of early versus late vasopressor administration. The definitions of early norepinephrine
ranged from prior to fluid resuscitation to less than
6 hours from onset of septic shock. As fluid overload
is associated with increased mortality, future studies
should better delineate a more explicit definition of
early norepinephrine initiation. Future studies should
also investigate the impact of early norepinephrine
use on long-term mortality, including the upcoming
Crystalloid Liberal or Vasopressors Early Resuscitation
in Sepsis trial (35).
Sedation and Analgesia
Nonsedation or Light Sedation in Critically Ill,
Mechanically Ventilated Patients. The Nonsedation or
Light Sedation in Critically Ill, Mechanically Ventilated
Patients (NONSEDA) trial was a multicenter, randomized, nonblinded study evaluating light sedation
versus nonsedation in mechanically ventilated patients
(9). Patients were randomized to receive either nonsedation or light sedation, defined as a Richmond
Agitation-Sedation Scale (RASS) –2 to –3. Patients in
www.ccejournal.org
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the light sedation group received propofol for the first
48 hours of mechanical ventilation then transitioned to
a continuous midazolam infusion per study protocol.
There was no difference in all-cause 90-day mortality between the nonsedation and light sedation groups (42.4% vs 37.0%; 95% CI, –2.2 to 12.2;
p = 0.65). Secondary outcomes included delirium-free
days, days without mechanical ventilation, and occurrence of thromboembolic events, of which no significant differences were found. Within the nonsedation
group, 27.0% required sedation on day 1 and 38.4%
received sedation at some time during their ICU stay,
with delirium being cited as the most frequent reason.
The safety outcome of self-extubation requiring reintubation within 24 hours was more common in the
nonsedation group versus light sedation group (8.9%
vs 4.0%, p = 0.01).
Sedation in ventilated patients has been an important topic, yet ideal standard definitions for light sedation and established protocols are not commonplace. A
meta-analysis of 8,001 mechanically ventilated patients
found a significantly higher mortality risk with those
receiving deeper levels of sedation (p = 0.003). Those
with lighter sedation were at risk of agitation-related
adverse events such as unintentional extubation
(p = 0.002); however, no difference in delirium was
identified (36). The Pain, Agitation/Sedation, Delirium,
Immobility, and Sleep (PADIS) guidelines favors nonbenzodiazepines for sedation owing to shorter time to
extubation (37). Light sedation is recommended over
deep sedation; however, the PADIS guidelines do not
specifically address nonsedation strategies in mechanically ventilated patients.
Prior to the NONSEDA trial, Strøm et al (38) evaluated a nonsedation strategy in a single-site medical/
surgical ICU. The investigators randomized 140 mechanically ventilated patients to receive either nonsedation or sedation protocols. Converse to the NONSEDA
trial, Strøm et al (38) found a significant improvement
in length of ventilation, ICU length of stay and hospital
length of stay when the nonsedation strategy was used.
Possible reasons the NONSEDA trial did not replicate
these results include the similar RASS scores between
groups and the high prevalence of sedation utilization
in the nonsedation group. The results of the NONSEDA
trial suggest that a nonsedation strategy is noninferior
to light sedation and that light sedation may be a safer
strategy to prevent harmful adverse effects such as
6     www.ccejournal.org

self-extubation. Nonsedation may be appropriate for a
select population but further trials are needed.
Dexmedetomidine for Reduction of Atrial
Fibrillation and Delirium After Cardiac Surgery:
A
Randomized
Placebo-Controlled
Trial.
Dexmedetomidine possesses sedative and sympatholytic
properties with minimal respiratory depression (10).
Previous data regarding use of dexmedetomidine
in cardiac surgery to reduce atrial fibrillation (AF)
have been inconclusive (39, 40). Dexmedetomidine
has been shown to reduce delirium postcardiac surgery; however, guidelines do not mention the use of
dexmedetomidine in this patient population (41, 42).
Guideline recommendations support the use of propofol over benzodiazepines for intubated patients
and dexmedetomidine use in mechanically ventilated
patients when agitation is inhibiting weaning of sedation and extubation; however, recommend against use
of dexmedetomidine to prevent delirium (37).
Turan et al (10) conducted a multicenter, randomized, placebo-controlled trial to evaluate dexmedetomidine’s effect on a coprimary outcome of atrial
arrhythmia and delirium in adult patients undergoing cardiac surgery with cardiopulmonary bypass and
heart rate greater than 50 beats/min. Secondary outcomes included kidney function, incisional pain, bradycardia and hypotension requiring treatment, stroke,
myocardial infarction, venous thromboembolism, surgical site infection, and mortality. Dexmedetomidine
was started preincision at 0.1 µg/kg/hr and escalated
to 0.2 µg/kg/hr at bypass termination. Postsurgery, the
infusion was increased to 0.4 µg/kg/hr and continued
for 24 hours. Managing providers reduced the dose
if hemodynamics necessitated, and additional sedatives, such as propofol and benzodiazepines, were used
based on discretion.
A total of 400 and 398 patients were randomized
in the dexmedetomidine and placebo groups, respectively, when the trial was terminated early. No difference in postoperative AF was observed in patients
receiving dexmedetomidine compared with placebo
(30% vs 34%; RR, 0.91; p = 0.34) and there was a
nonsignificant increase in delirium incidence among
patients in the dexmedetomidine group (17% vs 12%;
RR, 1.48; p = 0.026). More clinically significant hypotension was observed in the dexmedetomidine group
(57% vs 36%) and in a post hoc analysis, delirium
was more likely in patients with clinically significant
December 2021 • Volume 3 • Number 12
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hypotension (p = 0.009). These findings were consistent
across sites; patient demographics and measures were
relatively homogenous. Amiodarone prophylaxis was
prohibited and beta-blocker doses were not reported.
Additionally, benzodiazepine use was not described.
Turan et al (10) demonstrated dexmedetomidine failed to reduce incidence of AF and observed
increased hypotension and delirium, even at relatively
low doses. Based on lack of evidence to support dexmedetomidine to reduce AF and finding increased
delirium postcardiac surgery in this appropriately
powered trial, its use should be reserved for patients
requiring light sedation.
Stroke
Endovascular Thrombectomy With or Without
IV Alteplase in Acute Stroke (DIRECT-MT).
DIRECT-MT was a prospective, randomized, openlabel trial of 656 patients with acute ischemic stroke (12).
Adult patients with a large vessel occlusion and neurologic deficit, indicated with National Institute of
Health Stroke Scale (NIHSS) of at least two, who
could also be treated with alteplase within 4.5 hours
of symptom onset were included in the trial. Patients
with baseline disability, defined as score greater than 2
on modified Rankin Scale (mRS) or contraindication
to alteplase were excluded. Patients were randomized
to either thrombectomy alone (n = 327) or combination thrombectomy plus alteplase, dosed at 0.9 mg/kg
to a maximum of 90 mg (n = 329).
Patient characteristics at baseline were similar in
both groups with a median NIHSS score of 17. In an
intent-to-treat analysis, the adjusted common OR for
mRS score at 90 days was 1.07 (95% CI, 0.81–1.40;
p = 0.04) concluding thrombectomy alone was noninferior to combination thrombectomy. Mortality, serious adverse events, and procedural complications
were similar between groups.
Retrospective studies and meta-analyses have produced conflicting results on benefits of IV thrombolytics prior to thrombectomy; thus, this is the first RCT to
show noninferiority of thrombectomy alone over combination therapy (43–46). Despite achieving successful reperfusion in most patients, only ~36% of patients
had mRS of 0–2 at 90 days displaying the impact of
multiple factors on outcomes.
Limitations of this study are primarily related to
practice patterns in China differing to those in the
Critical Care Explorations

United States. Time from triage to randomization
was longer due to workflow (e.g., fewer prehospital
stroke activations and lengthy discussions with multiple family members regarding informed consent of
receiving alteplase). Thus, median time from symptom
onset to randomization was almost 170 minutes, significantly higher than a prior thrombectomy trial (47).
Additionally, the causes of stroke differ in Asian versus
non-Asian populations, making these results less
generalizable.
Alternative thrombolytics, such as tenecteplase, have
shown potentially improved outcomes. Encouraging
early reperfusion data was observed with tenecteplase
in a separate RCT that compared alteplase to
tenecteplase prior to thrombectomy (47). Thus, similar
trial design with tenecteplase may produce more compelling data for the combination therapy given the ease
of administration and promising reperfusion data (47).
Given the adverse events, cost, and strict exclusion criteria surrounding IV alteplase, it may be reasonable to
consider thrombectomy alone for patients in whom
risks of thrombolytic therapy outweigh the benefits.

CONCLUSIONS
This clinical review provides perspectives on influential critical care pharmacotherapy publications in
2020 along with insight on clinical practice impact.
Limitations of the article include the possibility of
missing relevant literature among unreviewed journals
as well as future considerations for ongoing publications surrounding sepsis, sedation, COVID-19, and
stroke. Further trials are needed to answer numerous
clinical questions surrounding these highly prevalent
disease states.
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APPENDIX A: JOURNALS
INCLUDED IN THE CLINICAL
PHARMACY AND PHARMACOLOGY
PHARMACOTHERAPY LITERATURE
UPDATE REVIEW
American Journal of Clinical Nutrition, American
Journal of Emergency Medicine, American Journal
of Health-System Pharmacy, American Journal of
Respiratory and Critical Care Medicine, Anesthesia
and Analgesia, Annals of Emergency Medicine,
Annals of Intensive Care, Annals of Pharmacotherapy,
Anesthesiology, CHEST, Circulation, Clinical
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Infectious Diseases, Clinical Toxicology, Critical
Care, Critical Care Explorations, Critical Care
Medicine, Intensive Care Medicine, JAMA, Journal
of Cardiothoracic and Vascular Anesthesia, Journal
of Critical Care, Journal of Intensive Care Medicine,
Journal of Neurotrauma, Journal of the American
College of Cardiology, Journal of Trauma and Acute
Care Surgery, Journal of Parenteral and Enteral
Nutrition, Lancet, Lancet Infectious Diseases,
Lancet Neurology, Lancet Respiratory Medicine,
Neurocritical Care, New England Journal of Medicine,
Pharmacotherapy, Resuscitation, Shock, and Stroke.
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